In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis
- 1 February 1984
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 25 (2), 279-280
- https://doi.org/10.1128/aac.25.2.279
Abstract
Amikacin, combined with aztreonam, piperacillin, or ticarcillin, synergistically inhibited amikacin-resistant sputum isolates of Pseudomonas aeruginosa and P. cepacia from children with cystic fibrosis. Ticarcillin-amikacin was the least active combination. Aminoglycoside resistance should not preclude the use of beta-lactam-aminoglycoside combinations in the treatment of pulmonary infections in cystic fibrosis.Keywords
This publication has 7 references indexed in Scilit:
- Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1983
- Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosisAntimicrobial Agents and Chemotherapy, 1982
- A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosisThe Journal of Pediatrics, 1981
- In-vitro antibacterial activity of SQ 26,776Journal of Antimicrobial Chemotherapy, 1981
- Antibacterial activity of the monobactam SQ 26,776 against antibiotic resistant enterobacteria, including Serratia spp.Journal of Antimicrobial Chemotherapy, 1981
- In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteriaJournal of Antimicrobial Chemotherapy, 1981
- Correlations between Methods for Measurement of SynergyThe Journal of Infectious Diseases, 1980